Cardiovascular diseases remain the leading cause of death worldwide and current treatment strategies have limited effect of disease progression. It would be desirable to have better models to study developmental and pathological processes and model vascular diseases in laboratory settings. To this end, human induced pluripotent stem cells (hiPSCs) have generated great enthusiasm, and have been a driving force for development of novel strategies in drug discovery and regenerative cell-therapy for the last decade. Hence, investigating the mechanisms underlying the differentiation of hiPSCs into specialized cell types such as cardiomyocytes, endothelial cells, and vascular smooth muscle cells (VSMCs) may lead to a better understanding of developmental cardiovascular processes and potentiate progress of safe autologous regenerative therapies in pathological conditions. In this review, we summarize the latest trends on differentiation protocols of hiPSC-derived VSMCs and their potential application in vascular research and regenerative therapy.
Introduction
During early mammalian development, the cardiovascular system is the primary organ system needed for development into a more complex organism. In this early stage of embryogenesis, the embryo acquires nutrients and oxygen by means of diffusion. With a growing embryo, however, the diffusion distance becomes too long, and the embryo adapts by establishing a highly branched tubular network to ensure proper distribution of gases, nutrients, hormones, and circulating cells. 1 These developmental processes are highly complex, and require delicate regulation and differentiation of stem cells and progenitor cells into endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) that become a pre-requisite for maintaining normal tissue homeostasis. Dysregulation and inadequate maintenance of these cells have serious consequences leading to numerous pathological conditions, including hypertension, atherosclerosis, and ischemia. These conditions constitute a growing social and economic burden. 2 Although pharmaceutical inventions and surgical procedures are available, these are not always possible or beneficial for all patients. An alternative that has gained attention is induction of new blood vessel formation by pro-angiogenic factors to improve blood perfusion in ischemic tissues. More than 25 clinical trials have evaluated the concept of gene transfer and growth factor delivery of pro-angiogenic factors such as vascular endothelial growth factors (VEGFs) and fibroblast growth factors (FGFs) but failed to demonstrate substantial functional improvement in patients suffering from cardiovascular diseases. 3 Therefore, new and more effective approaches are needed, with the ultimate goal of inducing neovascularization, improving blood perfusion, and restoring function by vascular regeneration. These goals can be achieved by cell-therapy, which aims at facilitating regeneration by delivery of either stem cells, progenitor cells, or terminally differentiated cells. 4 Especially cell-therapy using VSMCs and their progenitors have been shown to promote neovascularization, wound healing, and contractility. [5] [6] [7] [8] [9] [10] [11] Numerous in vitro differentiation protocols of VSMCs have been established from different cell sources and different induction methods, however, no standardized method exists. Currently, the most powerful and best suitable platform for developing a cell source for regenerative medicine as well as research applications appears to be induced pluripotent stem cells (iPSCs). This is due to the fact that it is now possible to study genotype-phenotype relations in a widespectrum of cell types and differentiation states without being hampered with source and number of cell. 12 In addition, iPSC technology has opened new avenues in disease modelling and drug discovery, which enables effective studies of developmental biology, toxicity screening of drugs, and discovery of new compounds for currently incurable diseases in vitro. 13 Here, we review the most recent advances in differentiating human iPSCs towards VSMCs with particular focus on monolayer-based approaches that have proved to be the most efficient, consistent, and scalable techniques currently available. Moreover, we will discuss the challenges related to the use of these cells for vascular research and cellbased therapies.
Embryonic origin and phenotypic modulation of VSMCs
The differentiation of stem cells into VSMCs comprises changes of cell functionality and morphology needed to meet the requirements of blood vessel development. VSMCs constitute the structural, muscular, and functional unit of blood vessels, in tunica media, mainly exhibiting contractile functions to control blood pressure and perfusion. 14 The embryonic development of de novo vessels, termed vasculogenesis, includes vessel formation from endothelial progenitor cells or angioblasts in the embryo. 15 Angioblasts coalesce and form the primitive vascular plexus, a honeycomb structure consisting of differentiated ECs. 16 Following the establishment of the primitive vascular plexus, angioblasts acquire either arterial or venous fates and bring about the dorsal aorta and cardinal vein without plexus intermediates. These primitive vascular structures are then used as 'templates' to expand, remodel and establish the circulation by angiogenesis. The newly formed vessels are subsequently specified into arteries, veins, and capillaries in which VSMCs, pericytes, and other supporting cells are recruited to stabilize vessels, depending of the vessel type. 17 Intriguingly, VSMCs are heterogenic in origin, thus in the embryo they arise from distinctive non-overlapping origins populated at specific anatomical locations in the adult human body 18 ( Figure 1 ). Tracing studies have suggested that VSMCs in the adult originate from the ectodermal neural crest and mesodermal lineages such as paraxial mesoderm (somite), lateral plate mesoderm (proepicardium, secondary heart field, splanchnic, mesothelium, and mesoangioblast). 18, 19 Ectodermal derived VSMCs give rise to the ascending aorta, aortic arch, pulmonary trunk, ductus arteriousus, subclavian artery, carotids, and the septation of the cardiac outflow tract, whereas mesodermal derived VSMCs give rise to aortic root, coronary arteries, descending aorta, visceral arteries, and mesenteric arteries. [19] [20] [21] Among mesoderm-derived VSMCs the coronary VSMCs originate from the proepicardium. In the proepicardial tissue, pericardial cells undergo epithelial-to-mesenchymal transition and thereby become VSMCs. These coronary VSMCs are derived from lateral plate mesoderm whereas VSMCs in the walls of descending thoracic aorta originate from paraxial mesoderm. Contrary to this, the secondary heart field gives rise to VSMCs in the root of aorta. Finally, the VSMCs found in mesenteric arteries are derived from the mesothelium. Thus, VSMC arising from different embryological origins have been observed in different vessels as well as within the same vessel segments, showing distinct boundaries with no intermixing of cells from different embryonic origins 21 ( Figure 1 ). Lineage dependent diversities of VSMCs have been shown to be important for progression of vascular disease susceptibility. Several studies have shown that despite anatomical relocation of aorta segments from different embryonic origins, vessels maintained original behaviour and that intrinsic differences of the vessel wall were responsible for development of atherosclerosis. [22] [23] [24] [25] [26] A human study involving 11890 individuals provide strong evidence for this phenomenon and thus confirm the notion that specific vascular constituents at defined anatomical locations and hence different embryonic origins are more prone for vascular diseases. An explanation may be that VSMC display specific variations in growth, gene expression, functional properties and respond differently to signalling cues dependent of their embryonic origin. 18 Neural crest derived VSMCs have been shown to require specific factors, i.e. transforming growth factor b (TGF-b) and myocardinrelated transcription factor-B (MRTF-B) for DNA synthesis, proliferation, and differentiation, while mesodermal and paraxial derived VSMCs do not require or are negatively effected under same conditions. 18, 21 Analogously, Angiotensin II have been shown to stimulate hyperplasia of ectodermal derived VSMCs but cause hypertrophic growth of paraxial derived VSMCs found in the same artery. 18, 21 Moreover, VSMCs of different embryonic origins have been shown to exhibit differential responses to the atherogenic cytokine interleukin-1b (IL-1b) resulting in varied expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs), which is known to induce vascular remodelling, atherogenesis, and aneurysm. [27] [28] [29] Interestingly, VSMCs display functional plasticity by switching between a quiescent contractile phenotype and a proliferative synthetic phenotype ( Figure 2 ). These phenotypes are morphologically distinct, and have different protein expressions, extracellular matrix (ECM) synthesis, proliferation, and migration rate. 18 During late embryogenesis and postnatal development VSMCs present the synthetic phenotype. Synthetic VSMCs do not poses contractile properties but are important for vascular maturation and vessel remodelling. 30, 31 In mature blood vessels VSMCs mainly adopt the contractile phenotype. In addition to the contractile proteins, these cells also express receptors, ion-channels, signal transduction molecules, and calcium regulatory proteins. 30, 31 This ability to switch from one phenotype to another is suggested to occur throughout development, during normal physiology and injury, and may have evolved to optimize the survival of higher organisms. 31 However, in certain vascular diseases, including atherosclerosis, hypertension and aneurysm the synthetic phenotype cannot revert back to the contractile phenotype and thus may play a detrimental pathophysiological role 32, 33 ( Figure 2) . Collectively, these results support the notion that lineage heterogeneity of VSMCs and functional plasticity may attribute to vascular diseases. Accordingly, a comprehensive mapping of the ontogeny of VSMCs and analysis of the molecular and cellular events that lead to VSMC induction, differentiation and modulation is important to assess the VSMC developmental origins as a susceptibility factor for vascular diseases. Such knowledge is also pivotal for our understanding of blood vessel morphogenesis in general.
Human iPSCs: a new source of pluripotent cells
The complexities in VSMC development due to differences in embryological origin and phenotypic properties have hindered establishment of efficient in vitro models and ultimately development of novel treatment options. However, nuclear reprogramming of adult somatic cells into iPSCs and the availability of human patient-derived iPSCs opens new possibilities. 34 51 Although caution and thorough investigations should be taken along with stem cell phenotype. Contractile VSMCs have a high expression of contractile genes, low rates of proliferation and migration. Morphologically, the contractile VSMCs display spindle shape with a heterochromatic nucleus, decreased synthetic organelles, and abundant myofilaments. Conversely, synthetic VSMCs have high rates of proliferation and migration, low expression of contractile genes, and exhibit extensive ECM production, including collagen, elastin, proteoglycans, cadherins, and integrins, which constitute a major part of the blood vessel mass. Morphologically, the synthetic VSMCs adopt a rhomboid shape with extensive rough endoplasmic reticulum, golgi, ribosomes, an euchromatic nucleus, and no specific filamentous cytoplasm. Intrinsic factors and environmental cues have been suggested to affect the phenotype of VSMCs. For example, in vascular disease, the VSMCs mainly present the synthetic phenotype.
. therapy, iPSCs facilitates new standards for cell-therapy in clinical purposes and may constitute a new treatment strategy for diseases that were previously thought as incurable. 52 
hiPSC differentiation towards mesodermal precursors
In this review, we focus on mesodermal derived VSMC precursors as the majority of in vitro differentiation protocols of hiPSCs towards VSMCs is derived from this lineage. Pluripotent stem cells from the inner cell mass (ICM) of blastocyst undergo morphogenetic movement of gastrulation in the early stages of development where undifferentiated cells migrate through the primitive streak to position the mesoderm between the ectoderm and endoderm. The formation of the primitive streak is therefore considered as the initial step of specification where undifferentiated cells are directed to generate all mesodermal and endodermal tissue lineages, collectively called mesendoderm 53 ( Figure 3) . Genes expressed at this early stage of mesoderm development include Eomesodermin (EOMES), MIXL1, Brachyury (T), FOXA2, WNT3, and MESP1. 53 These factors are the major molecular determinants in the patterning and induction of mesoderm. Particularly, Brachyury has been shown to be important for proper specification of mesoderm and correct movement trough the primitive streak, whilst EOMES and MIXL1 have been suggested to have an important role in endoderm differentiation and act as negative regulators of Brachyury. 54, 55 Accordingly, Brachyury is used as an early specific marker for mesoderm differentiation. [54] [55] [56] Moreover, members of the TGF-b family, including BMPs, Activin/Nodal together with Wnt signalling and FGFs have been shown to be important inducers for patterning of mesoderm and are engaged in autoregulatory loops that regulates this process ( Figure 3) . 53, 57 As a result, cells migrate from the primitive streak along a BMP4 concentration gradient and form mesoderm subtypes, which include axial, paraxial, intermediate, and lateral plate mesoderm. Early events of mesoderm specification play a significant role in vascular physiology and pathology. 6, 18, 20 Accordingly, attention has been drawn towards factors that direct stem cells into mesoderm subtypes, i.e. that high levels of Activin/Nodal induced definitive endoderm, whereas activation of the Wnt/b-catenin pathway and low levels of Activin/Nodal induced lateral (CD34 þ , KDR þ ) and paraxial (CD34 -, PDFGRa þ ) mesoderm. 58, 59 Similarly, it has been reported that Activin/ Nodal or BMP4 induced mesoderm subtypes in the presence of FGF-2 and PI3K inhibitor. 56 
Directing the differentiation of hiPSC towards VSMCs
Multiple studies performed in vivo as well as in vitro cell cultures have helped identify selective markers to define and track the differentiation process of stem cells into VSMCs at specific stages throughout development. Moreover, several epigenetic and miRNA regulators have been shown to impact the VSMC differentiation and phenotype. It has been shown that deletion of enzymes important for miRNA synthesis, result in embryonic lethality caused by reduction in VSMC proliferation, in mice and sustained expression of pluripotentcy markers in ES cell after induction of differentiation into VSMC. 60, 61 However, despite the extensive literature, better markers and methods to verify differentiated VSMCs in vitro is needed.
Cell culture methodologies to differentiate hiPSCs to VSMCs include (i) the formation of cell aggregates in non-adherent spheroids, called embryoid bodies (EBs), (ii) monolayer based approaches where signalling pathways and culture conditions are manipulated to obtain a desired cell type, and (iii) co-culture with stromal cells. We will focus on the EB ( Table 1 ) and monolayer ( Table 2 ) differentiation methods since coculture is rarely used. The tables show an overview of the current protocols used to characterize VSMCs differentiation from hiPSCs. Table 3 shows an overview of the various characterization methods to verify the VSMC phenotypes.
Characterization of VSMCs in vitro
The first VSMC marker identified, alpha smooth muscle actin (aSMA), has been used extensively to verify VSMC differentiation. 62 However, aSMA is also expressed in myofibroblasts, cardiomyocytes, and skeletal myocytes indicating that aSMA alone is not sufficient to define a pure VSMCs population. 31, 62, 63 
Embryoid body derived VSMC differentiation
By allowing hiPSCs to form three-dimensional EBs in differentiation medium with or without growth factors, it is possible to induce spontaneous or directed differentiation that recapitulates embryonic development similar to gastrulation of an epiblast stage embryo in vivo. [65] [66] [67] [68] [69] [70] [71] Following EB formation, cells of interest are selected or plated directly in polymercoated surfaces such as collagen IV, fibronectin, gelatin, or matrigel in medium containing growth factors important for differentiation. Early studies on hiPCS to form EBs and subsequently VSMCs were based on protocols established for ESCs. 65, 67 The generated VSMCs could respond to vasoactive agonist and expressed the early VSMC markers, aSMA, SM22a, and CNN1 65,67 ( Table 1) . In agreement with these data several studies have generated iPSCs from patient specific cells and differentiated these into VSMCs while studying the diseased phenotype. This clearly illustrates the plasticity of VSMCs and may explain the difficulties of identifying a single progenitor that give rise to VSMCs. However it is plausible that some of the above mentioned cell types or populations, although identified by distinct molecular markers, actually may represent the same or similar population. Thus the extent of overlap or unique identity between the distinct populations in the various studies is unknown. Although the EB differentiation method offers some advantages, several weak points needs to be taken into account. The cell size of EBs, oxygen tension, nutrient gradient and mechanical forces may influence the differentiation of the cells. 75 Although, morphogens (i.e.
cytokines, growth factors, and growth factor inhibitors) direct the differentiation, 76 they may only exert their function on cells on the exterior of the EB resulting in a heterogeneous cell population.
12,77
Adherent monolayer differentiation
To reduce the complexity of the cell culture system, monolayers containing polymers can be used to conduct differentiation. The monolayer system allows the cells to receive a homogenous amount of nutrients and growth factors ensuring a more identical cell population during differentiation ( Table 2) . Like the EB-based protocols, experiments with monolayer differentiation have examined the selection of specific progenitor populations as origin for VSMC. [78] [79] [80] [81] [82] [83] The first protocol established using cell sorting of hiPSCs in monolayers, was based on a ESC protocol, isolating the Flk1 þ ,
VE-cadherin -
, and TRA1 -cell populations. 78 Other studies induced hiPSCs towards CD34 þ and CD31 þ cells. [79] [80] [81] [82] [83] Within this strategy various methods have been used to mimic the embryology and development of primitive streak/mesodermal cells ( Figure 3 ) including media supplemented with growth factors 79, 82, 83 or activation of the Wnt-signalling pathway using the small molecule, CHIR99021. 80, 81 After selection for either CD34 þ cells alone or in combination with CD31 þ cells, VSMC differentiation have been initiated using differentiation medias with PDGF-BB alone or in combination with FGF-2 or TGF-b1 ( Table 2 ).
79-83
All studies obtained aSMA and CNN1 positive cells. 89 12
Wanjare et al. (2013) contract when treated with carbachol. 79, 82 Generally, cell sorting can increase the concentration of the mesodermal cells of interest, however, cell sorting may reduce the viability of the pre-cursors and result in a variable differentiation. Moreover, these studies do not specify whether VSMCs display a contractile or synthetic phenotype. In this regard, several studies have established differentiation protocols that circumvent cell sorting and focus on the phenotype of VSMCs 9,84-87 ( Table 2 ). The synthetic VSMC phenotype has been achieved with high concentrations of PDGF-BB alone 87 or in combination with TGF-b 9,88 in these studies.
In addition, Wanjare et al. found that high serum concentration in conjunction with PDGF-BB and TGF-b promotes the synthetic phenotype whereas low serum and TGF-b promoted the contractile phenotype. 9, 87 In contrast, the contractile phenotype has been achieved in numerous ways including low PDGF-BB concentrations and TGF-b followed by lactate metabolic medium, 85 heparin/Activin A, 84 and heparin/TGF-b. 86 Validating of the differentiated VSMC showed that both early and late VSMC markers were increased in the contractile VSMCs as well as in the synthetic VSMCs although to a lesser extent. 9, 85 Functional studies showed that synthetic VSMCs exhibited higher migration rate compared with contractile VSMCs, whereas the contractile phenotype contracted more extensively in response to vasoactive agents than synthetic VSMC verifying correct phenotype and functional characteristics. 9, [84] [85] [86] [87] Despite the many differentiation protocols of hiPSCs to functional VSMCs none of them has addressed the lineage-specific derivation of VSMCs. Three recent studies have extended a protocol from ESC 59 to hiPSC and reported significant findings of linage-specific derivation of VSMCs. They mimicked the embryonic BMP concentration along the primitive streak resulting in direction of uncommitted mesodermal cells to paraxial mesoderm and lateral plate mesoderm. 6, 56, 88 Moreover, they were able to differentiate hiPSCs towards neuroectodermal cells. 6 Similarly, lateral plate mesoderm cells can be differentiated to epicardial cells by a combination of WNT3A, BMP4, and retinoic acid. 19 Further differentiation to VSMC was obtained similarly from all intermediate origins using PDGF-BB and TGF-b and verified by the presence of mature VSMC markers, contraction to carbachol 6, 56, 88, 19 and the capability to promote blood vessel formation in vivo. 6 Moreover, functional epicardial derived VSMCs were verified by a decreased LDL uptake when treated with statins, which is a key pathophysiological steps in atherogenesis. 19 Interestingly, global gene expression profiling showed that over 400 genes were uniquely expressed between the VSMCs subtypes, indicating that each subtype may have a unique genetic and functional lineagedependent signature. 6 In line with this, the neuroectoderm derived VSMCs responded differently than mesodermal derived VSMCs to specific stimuli. Silencing of MRTF-B/MKL2 lead to inhibited growth, whereas stimulation with TGF-b or Angiotensin II increased the proliferation as compared with mesoderm derived VSMCs that was not affected. 6 These results strongly correlate with previous in vivo studies, demonstrating that VSMC subtypes could be used to study origin-dependent disease susceptibility. 18, 21 Many other protocols have been tested with great potential,
i.e. differentiation of hiPSCs to VSMC on de-cellularized aortic grafts, using growth factors such as PDGF-BB together with shear stress. 89 However, biomechanical (uniaxial and circumferential) strain haven been proved to effect VSMC in different ways 87 and thus may be important in modulating the phenotype and function of VSMCs in tissue-engineered vessels. Taken together, numerous advances in the origin, expansion, and functional analysis of VSMCs derived from hiPSC have been made in the past years. It appears that many protocols efficiently obtain purified and expandable hiPSCs derived VSMCs thus giving an encouraging outlook for future regenerative applications. Nonetheless, there are major obstacles that need to be addressed with current in vitro differentiation protocols. Although many of the differentiation protocols we have examined herein provide evidence for structural and contractile proteins, a majority of the studies fails to verify the expression of VSMC specific SM-MHC and smoothelin. Moreover, numerous studies do not provide evidence for modulation of Ca 2þ transients or ability to contract in response to vasoactive agents (Table 3) . This lack of terminal VSMC verification may be due to shorttime differentiation or use of serum in differentiation media, factors stimulating VSMC migration, proliferation and ECM synthesis. Moreover epigenetic modifications and miRNAs play an important role in guiding the differentiation in vivo. Especially, miR-143/miR-145, miR-21, and miR-133 have been reported to play a role in VSMC differentiation in mice through the major regulators of VSMC differentiation and phenotype (TGF-b, BMP4, SRF-myocardin/MRTF). 90, 91 In contrast PDGF-BB has been shown to induce the dedifferentiation process in VSMC through miR-221 and negatively regulate the expression of miR-133 through ERK1/2 kinase dependent pathway. 96 Also miR-1, miR-146a, and miR-130a have been assigned impact on VSMC phenotype, proliferation and migration.
Currently it is uncertain whether the established protocols recapitulate these differentiations cues in vitro. All these factors, is of great concerns as they complicate the manifestation of mature contractile VSMC that can be used to vascular engineering, screen for drugs or as cell therapy.
hiPSC derived VSMCs as tool for disease modelling
Traditionally, animal models are extensively used to investigate human diseases and elucidate pathophysiological mechanisms; however, there are many biological differences between rodents and humans. A systematic study of inflammation have concluded that changes in gene expression in mice had little or no correlation with the gene expression changes seen in humans. 92 Similarly, many drugs that have proved to be effective in mice have been ineffective in human clinical trials. 93 Transgenic animal models have helped to avoid species to species differences but the generation and breeding is costly and slow. Thus a human model is required. In this regard, hiPSCs hold the potential to model cell or gene specific diseases in vitro. Moreover, hiPSCs generated from patients contains both the genetic background and mutation needed for full appearance of the disease 13, 94 ( Figure 4) . Human iPSC-VSMCs generated from patients suffering from either supravalvular aortic stenosis (SVAS) or Williams-Beuren syndrome (WBS) patients were found to be highly proliferative, have low expression of early and mature VSMC markers and impaired VSMC functionality. 65, 72 Using these hiPSC-VSMC models the researchers found that the disorganized aSMA filament phenotype in VSMCs from SVAS patients could be rescued using recombinant elastin or small GTPase RhoA. 65 Similarly, treatment with elastinbinding protein ligand 2 or the anti-proliferative drug rapamycin could treat the VSMCs lacking elastin and thus rescue the abnormal WBSVSMCs. 72 Several studies, using patients-derived hiPSC have been able to recapitulate and investigate the mechanisms leading to degeneration of VSMCs in Hutchinson-Gilford Progeria (HGP) syndrome. 73, 83, 95 Likewise, a recent paper by Granata et al. showed that Marfan syndrome patient-derived VSMCs are extremely valuable as disease models to identify novel treatment strategies to rescue the mutated protein Fibrilin-1 causing multisystem problems with the connective tissue including thoracic aorta aneurysms. 88 Collectively, these studies demonstrate that patient derived hiPSCs serve as a powerful tool to study 6 Various studies have been focusing on developing tissue engineered vascular grafts (TEVG), and some have placed attention on the regenerative capability of hiPSC-derived VSMCs progeniprogenitors. 8, 67, 70, 79, 84, 98 In general, VSMC seeded into the specific grafts either alone or in combination with ECs, were able to form vascular tissue when implanted in SCID mice, 67, 84, 89, 98 express at least one of the VSMC markers alone or in combination with EC-specific markers (CD31 and CD144). 67, 89 A single study described that 25% of the grafts in SCID mice formed teratomas. 98 70, 79 Collectively, these studies suggest that transplanted progenitor cells can restore tissue function by direct contribution to neovascularization or through paracrine secretion of proangiogenic factors and thus, holds great therapeutic potential to enhance revascularization.
Conclusion
It is now feasible to generate a clinically relevant number of VSMCs from hiPSCs, providing a strong platform for disease modelling but also for potential use of repairing damaged vasculature and treating ischemic diseases. However, important questions remain to be answered, concerning standardized protocols for hiPSC reprogramming, differentiation, selection, and delivery. Moreover, significant efforts should be made to investigate the stability of hiPSC derived VSMCs and the most suitable cell type for cell therapy; VSMC vs. progenitors. Finally, procedures to investigate and avoid teratoma formation, contamination and genetic abnormalities should be standardized. Figure 4 Illustration of regenerative applications of hiPSC. hiPSCs have the potential to model and treat human diseases. Patient-specific iPSCs can be obtained and differentiated into different cell types with the same genetic background as the donor patient, providing the opportunity to study pathogenesis in vitro and potential drugs can be screened aiding in the discovery of novel therapeutic compounds. Examples of human diseases that have been studied using patient-derived hiPSCs include supravalvular aortic stenosis (SVAS), William-Beuren syndrome (WBS), Marfan and Hunchinson-Gilford Progeria syndrome (HGPS). Common for these diseases is mutations or lack of certain genes encoding crucial proteins for VSMC functionality. In SVAS and WBS patients the Elastin gene is either mutated or deleted, creating disorganized aSMA filaments, hyper-proliferative VSMC and aortic malfunction. In both cases the patient specific hiPSC derived-VSMC phenotype can be rescued using recombinant Elastin or the anti-proliferative drug rapamycin. Marfan syndrome is a multisystem disorder of connective tissue caused by mutation in the matrix protein Fibrilin-1 giving rise to aortic aneurysms. In Hutchinson-Gilford Progeria syndrome, a human pre-mature aging disorder, the gene Lamin A is mutated causing a truncated version named Progerin. The generated patient specific hiPSCs have been used to study these rare diseases and to identify novel treatment strategies.
